These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 34932096)

  • 21. Using Therapeutic Drug Monitoring to Identify Variable Infliximab Metabolism in an Individual Patient With Ulcerative Colitis.
    Stein BN; Pellish RS; Thompson KD; Baptista V; Siegel CA
    J Clin Gastroenterol; 2016 Jan; 50(1):66-8. PubMed ID: 26191643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Usefulness of therapeutic monitoring of infliximab in the treatment of inflammatory bowel disease].
    Quera R; Moreno M; Simian D; Ibáñez P; Lubascher J; Figueroa C; Flores L; Kronberg U; Pizarro G; Fluxá D
    Rev Med Chil; 2018 Nov; 146(11):1241-1251. PubMed ID: 30725037
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels.
    Novakovic V; Abdija S; Larsen PB; Fenger M; Gredal L; Jacobsen KK
    Clin Biochem; 2019 Dec; 74():73-75. PubMed ID: 31669514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bayes-based dosing of infliximab in inflammatory bowel diseases: Short-term efficacy.
    Santacana Juncosa E; Rodríguez-Alonso L; Padullés Zamora A; Guardiola J; Rodríguez-Moranta F; Serra Nilsson K; Bas Minguet J; Morandeira Rego F; Colom Codina H; Padullés Zamora N
    Br J Clin Pharmacol; 2021 Feb; 87(2):494-505. PubMed ID: 32495380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring.
    Lucidarme C; Petitcollin A; Brochard C; Siproudhis L; Dewitte M; Landemaine A; Bellissant E; Bouguen G
    Aliment Pharmacol Ther; 2019 Jan; 49(2):147-154. PubMed ID: 30589970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
    Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
    Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proactive Versus Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: Is the Juice Worth the Squeeze?
    Franco DL; Click B
    Inflamm Bowel Dis; 2020 Jan; 26(1):112-113. PubMed ID: 31184363
    [No Abstract]   [Full Text] [Related]  

  • 28. Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease.
    Gil Candel M; Gascón Cánovas JJ; Urbieta Sanz E; Gómez Espín R; Nicolás de Prado I; Iniesta Navalón C
    Rev Esp Enferm Dig; 2020 May; 112(5):360-366. PubMed ID: 32338010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
    Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TDM of Anti-TNF Agents: The Importance of Being Active!
    Annese V
    Inflamm Bowel Dis; 2020 Jan; 26(2):271-272. PubMed ID: 31247072
    [No Abstract]   [Full Text] [Related]  

  • 31. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease.
    Sánchez-Hernández JG; Rebollo N; Martin-Suarez A; Calvo MV; Muñoz F
    Br J Clin Pharmacol; 2020 Jun; 86(6):1165-1175. PubMed ID: 32022291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
    Syversen SW; Goll GL; Jørgensen KK; Sandanger Ø; Sexton J; Olsen IC; Gehin JE; Warren DJ; Brun MK; Klaasen RA; Karlsen LN; Noraberg G; Zettel C; Ljoså MKA; Haugen AJ; Njålla RJ; Bruun TJ; Seeberg KA; Michelsen B; Strand EK; Skorpe S; Blomgren IM; Bragnes YH; Dotterud CK; Thune T; Ystrøm CM; Torp R; Mielnik P; Mørk C; Kvien TK; Jahnsen J; Bolstad N; Haavardsholm EA
    JAMA; 2021 May; 325(17):1744-1754. PubMed ID: 33944876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
    D'Haens G; Vermeire S; Lambrecht G; Baert F; Bossuyt P; Pariente B; Buisson A; Bouhnik Y; Filippi J; Vander Woude J; Van Hootegem P; Moreau J; Louis E; Franchimont D; De Vos M; Mana F; Peyrin-Biroulet L; Brixi H; Allez M; Caenepeel P; Aubourg A; Oldenburg B; Pierik M; Gils A; Chevret S; Laharie D;
    Gastroenterology; 2018 Apr; 154(5):1343-1351.e1. PubMed ID: 29317275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Editorial: is it time for therapeutic drug monitoring of anti-TNF agents during pregnancy? Maybe, maybe not.
    Kane S
    Aliment Pharmacol Ther; 2017 Jun; 45(12):1555-1556. PubMed ID: 28503863
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of three immunoassays for infliximab trough level monitoring in paediatric inflammatory bowel diseases.
    Villemonteix J; Guérin-El Khourouj V; Hugot JP; Giardini C; Carcelain G; Martinez-Vinson C
    Biologicals; 2021 Apr; 70():17-21. PubMed ID: 33676831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.
    Guidi L; Pugliese D; Panici Tonucci T; Berrino A; Tolusso B; Basile M; Cantoro L; Balestrieri P; Civitelli F; Bertani L; Marzo M; Felice C; Gremese E; Costa F; Viola F; Cicala M; Kohn A; Gasbarrini A; Rapaccini GL; Ruggeri M; Armuzzi A
    J Crohns Colitis; 2018 Aug; 12(9):1079-1088. PubMed ID: 29860436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease.
    Papamichael K; Vajravelu RK; Osterman MT; Cheifetz AS
    Dig Dis Sci; 2018 Mar; 63(3):761-767. PubMed ID: 29340807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease.
    Curci D; Lucafò M; Cifù A; Bramuzzo M; Martelossi S; Favretto D; De Pellegrin F; Fabris M; Vascotto F; Naviglio S; Ventura A; Stocco G; Decorti G
    J Pediatr Gastroenterol Nutr; 2019 Oct; 69(4):474-479. PubMed ID: 31149938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum trough infliximab and anti-infliximab antibodies in a cohort of gastroenterology and rheumatology patients' infliximab therapeutic drug monitoring.
    Barlow NL; Mohammed P; Berg JD
    Ann Clin Biochem; 2016 Jul; 53(Pt 4):477-84. PubMed ID: 26290514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience.
    Mitchell RA; Shuster C; Shahidi N; Galorport C; DeMarco ML; Rosenfeld G; Enns RA; Bressler B
    Can J Gastroenterol Hepatol; 2016; 2016():5203898. PubMed ID: 27957480
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.